Literature DB >> 11506956

Chromosome 9 aberrations by fluorescence in situ hybridisation in bladder transitional cell carcinoma.

P Eleuteri1, M G Grollino, D Pomponi, R De Vita.   

Abstract

To investigate the role of the monosomy 9 in bladder carcinogenesis, 96 cases of superficial bladder transitional cell carcinoma (TCC) were studied and followed periodically for around 3 years (mean+/-standard error of the mean (SEM); 3.46+/-0.34 years). Samples from bladder washings were analysed by fluorescent in situ hybridisation (FISH) to detect numerical anomalies of chromosome 9. Moreover, to evaluate the relative under representation of this chromosome, we detected numerical changes of chromosome 8 and DNA ploidy by flow cytometric analysis (FCM). Chromosome 8 copy number were related to FCM DNA ploidy and both were related with tumour grade. Monosomy 9 did not correlate with tumour grade, stage, chromosome 8 aneuploidies and abnormal DNA content, but correlated with tumour progression. Comparing the results in the primary and subsequent tumours, we observed an increase in the frequency of aneuploidies by FCM, associated with an increase of chromosome 8 polysomies. The mean chromosome 9 copy number/nucleus remained nearly the same in most of the primary and invasive tumours. Our results confirm that monosomy 9 is an early event and that it is retained during tumour progression and invasion and that the loss occurs before the tetraploidisation process. The relationship between the presence of a sub-population with monosomy 9 and tumour progression suggests the presence of a region that could have a role in the progression of superficial bladder TCC.

Entities:  

Mesh:

Year:  2001        PMID: 11506956     DOI: 10.1016/s0959-8049(01)00151-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  1 in total

1.  Fluorescence in situ hybridization in paraffin tissue sections: pretreatment protocol.

Authors:  A D Watters; J M S Bartlett
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.